Hemangeol and Leucovorin Calcium

• Generic Name: propranolol
• Dosage Forms: oral solution
• Other Brand Names: Hemangeol, Inderal LA, Inderal XL, InnoPran XL, Inderal, InnoPran XL

Hemangeol is a beta-blocker. Beta-blockers affect the heart and circulation (blood flow through arteries and veins).

Hemangeol is used to treat tremors, angina (chest pain), hypertension (high blood pressure), heart rhythm disorders, and other heart or circulatory conditions. It is also used to treat or prevent heart attack, and to reduce the severity and frequency of migraine headaches.

Hemangeol (Hemangeol oral liquid 4.28 milligrams) is given to infants who are at least 5 weeks old to treat a genetic condition called infantile hemangiomas. Hemangiomas are caused by blood vessels grouping together in an abnormal way. These blood vessels form benign (non-cancerous) growths that can develop into ulcers or red marks on the skin. Hemangiomas can also cause more serious complications inside the body (in the liver, brain, or digestive system).

Hemangeol may also be used for purposes not listed in this medication guide.

• Generic Name: leucovorin
• Dosage Forms: n.a.
• Other Brand Names: Wellcovorin

Antidote for unintentional overdosage of methotrexate (e.g., resulting from impaired elimination) and other folic acid antagonists (e.g., pyrimethamine, trimethoprim).

IV rescue therapy after high-dose methotrexate regimen (to control duration of exposure of sensitive cells to methotrexate) in the treatment of osteosarcoma (designated an orphan drug by FDA for this use).

Prevention of hematologic toxicity associated with pyrimethamine, trimethoprim, or trimetrexate therapy.

IV treatment of folate deficient megaloblastic anemias (e.g., serum folate concentration <0.002 mcg/mL) of infancy, pregnancy, sprue, and nutritional deficiencies when oral folic acid therapy is not feasible. No advantage over folic acid injection since ability to convert folic acid to tetrahydrofolic acid (THF) is not impaired in these anemias.

Effective in the treatment of megaloblastic anemia resulting from congenital dihydrofolate reductase deficiency.

Not effective in the treatment of pernicious anemia and other megaloblastic anemias secondary to lack of vitamin B12; avoid such use. (See Contraindications under Cautions.)

Adjunct to fluorouracil to prolong survival in the palliative treatment of advanced colorectal cancer (designated an orphan drug by FDA for this use).

First-line therapy for management of advanced colorectal cancer in a combination regimen consisting of fluorouracil, leucovorin, and either irinotecan or oxaliplatin.